Vivimed Labs Limited has officially postponed its board meeting that was scheduled to take place on February 13, 2026, for the approval of its third quarter FY 2026 financial results. The pharmaceutical company communicated this development to both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) through a formal notice dated February 11, 2026.

Meeting Postponement Details

The company's communication, signed by Company Secretary Yugandhar Kopparthi, informed the stock exchanges about the postponement without specifying the reasons for the delay. The original meeting was intended to approve the financial results for the third quarter of FY 2026.

Regulatory Compliance and Trading Window

Vivimed Labs has assured that it will intimate the revised date for the board meeting to the stock exchanges in due course. In compliance with regulatory requirements, the company has confirmed that the trading window for dealing in its securities will remain closed for designated persons until 48 hours after the declaration of the financial results following the rescheduled meeting.

Stock Exchange Information

The company trades on both major Indian stock exchanges with BSE code 532660 and NSE symbol VIVIMEDLAB. The formal communication was addressed to both exchanges as part of the mandatory disclosure requirements for listed companies.

Company Background

Vivimed Labs Limited operates with its registered office located at Kolhar Industrial Area, Bidar, Karnataka, and maintains its corporate office in Hyderabad, Telangana. The company is incorporated under CIN L02411KA1988PLC009465 and has been a listed entity on Indian stock exchanges.

Vivimed Labs Limited has announced the resignation of its Chief Financial Officer, Mr. Phaninder Nath P S, effective February 06, 2026. The pharmaceutical company informed stock exchanges about this key management change through a regulatory filing under SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Resignation Details

The company disclosed that Mr. Phaninder Nath P S tendered his resignation due to personal health issues. In his resignation letter, he mentioned the need to undergo treatment for health problems that have been aggravating over the past few weeks.

Regulatory Compliance

The resignation will result in Mr. Phaninder Nath P S ceasing to be Key Managerial Personnel under Section 203 of the Companies Act, 2013, and Senior Management Personnel under Regulation 30(5) of the SEBI Listing Regulations. This change affects his role in determining materiality of events or transactions for required stock exchange disclosures.

Vivimed Labs has fulfilled its regulatory obligations by notifying both BSE (Code: 532660) and NSE (Symbol: VIVIMEDLAB) about this development. The company provided all required details as per SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Management Transition

In his resignation letter, Mr. Phaninder Nath P S expressed gratitude to the Board for their support and cooperation during his tenure. He wished the company continued success in its future endeavors. The resignation letter was signed by Company Secretary Yugandhar Kopparthi on behalf of Vivimed Labs Limited.

The company has indicated it will initiate necessary filings with stock exchanges and the Ministry of Corporate Affairs as per applicable regulations. Vivimed Labs Limited, incorporated in 1988, operates from its registered office in Kolhar Industrial Area, Bidar, Karnataka, with corporate offices in Hyderabad, Telangana.